Background: The relationship between fasting blood glucose and urea in non-diabetic individuals is still unclear. This study aimed to evaluate the association between fasting blood glucose and urea in ...

Immunohistochemistry results further demonstrated increased insulin and PDX-1 expression, along with reduced glucagon levels in UCMSCs-treated rats. Additionally, liver and kidney function ...

Gvoke PFS (a pre-filled syringe) and Gvoke Kit. It is also involved in another collaboration with the product, working with Beta Bionics to supply the liquid glucagon that would be included in a ...

Ashok P Hinduja, Chairman of IndusInd International Holdings Ltd (IIHL), stated on March 18 that it is an ideal time for the company to increase its stake in IndusInd Bank. Hinduja expressed his ...

According to Monday’s news release, the candidate, OPK-88006, is set to be the first oral GLP-1/glucagon agonist to start human studies. Under the terms of the agreement, OPKO and Entera will split ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures,” said Kevin McCulloch, President and COO of Xeris. “American Regent is the ...

A legislative committee today heard testimony on a bill to limit needle and syringe exchange programs to one new needle or syringe for every used one brought in. But advocates said the proposal is a ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

Gvoke and Gvoke VialDx are not approved for continuous infusion. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks Gvoke VialDx in patients with ...

Xeris has 3-4 approved products; these are: Gvoke (glucagon injection): Gvoke is the first autoinjector for severe hypoglycemia approved by the FDA. Keveyis (dichlorphenamide): The first FDA ...